Journal: Endocrine-related cancer

Article Title: Bortezomib sensitizes thyroid cancer to BRAF inhibitor in vitro and in vivo

doi: 10.1530/ERC-17-0182

Figure Lengend Snippet: (A) Immunohistochemistry of PTC-bearing BRAFV600E using NF-κB-, Ki67- and Cyclin-D1-specific antibodies. Advanced PTC and goiter were stained with anti-NF-κB, KI67 or Cyclin D1 as indicated in PTC (right lane) and goiter (left lane). Magnification was 40×. (B) Immunofluorescence staining of PTC with VE1 and/or NF-κB. (C) Western blot analysis of the thyroid cancer cell lines (NPA, DRO, SW1736) expressing mutated BRAFV600E and the thyroid cancer cell line (KAT18) expressing BRAFwt up on the expression of BRAFV600E and activation of NF-κB. GAPDH was used as internal control for loading and transfer.

Article Snippet: Cell culture The human anaplastic thyroid carcinoma-derived cell lines, SW1736 and KAT18 cells were provided by Dr Xing (University of Johns Hopkins, Baltimore, MD, USA).

Techniques: Immunohistochemistry, Staining, Immunofluorescence, Western Blot, Expressing, Activation Assay, Control

Journal: Endocrine-related cancer

Article Title: Bortezomib sensitizes thyroid cancer to BRAF inhibitor in vitro and in vivo

doi: 10.1530/ERC-17-0182

Figure Lengend Snippet: Cell viability assay in TC cells. (A) DRO, SW1736 and KAT18 cells were treated with Vemurafenib (0–10 μM) and Bortezomib (0–100 nM) for 120 h, and cell viability was assayed by WST-8 assay. (B) NPA, DRO, SW1736 or KAT18 cells were exposed to sub-IC50 concentrations of Vemurafenib (0.1, 0.1, 1.0 or 10 μM) and Bortezomib (15, 15, 20 or 35 nM), respectively, for 72 h, and cell viability was tested by Trypan blue nuclear exclusion assay. B; Bortezomib; V; Vemurafenib. (C) SW1736 cells were treated with Vemurafenib (1.0 μM) and Bortezomib (20 nM) for 14 days and assessed by colonogenic assay.

Article Snippet: Cell culture The human anaplastic thyroid carcinoma-derived cell lines, SW1736 and KAT18 cells were provided by Dr Xing (University of Johns Hopkins, Baltimore, MD, USA).

Techniques: Viability Assay, Exclusion Assay

Journal: Endocrine-related cancer

Article Title: Bortezomib sensitizes thyroid cancer to BRAF inhibitor in vitro and in vivo

doi: 10.1530/ERC-17-0182

Figure Lengend Snippet: Drug combination induces apoptosis and cell cycle arrest in TC cells. (A) DRO and SW1736 cells were treated with Vemurafenib (0.1 or 1.0 μM) and Bortezomib (10 or 20 nM) for 48 h. TC cells were stained with propidium iodide and anti-Annexin V. The percentage of apoptotic cells is indicated (*P < 0.05, **P < 0.01). (B) SW1736 cells were treated with Vemurafenib and/or Bortezomib, and cell cycle progression was assessed by flow cytometric assay. (C) Western blot analysis demonstrates the phosphorylation and the corresponding degradation of IKBα and cleavage of PARP in control and treated SW1736 and DRO cells. GAPDH is used as an internal control for loading and transfer. Data are representative of three independent experiments. (D) Flow cytometry analysis of treated and control cells following the JC-1-staining shows the loss of mitochondrial membrane potential in response to the exposure of TC cells to the combination therapy. (E) Flow cytometry analysis of the reactive oxygen species (ROS) in control and treated TC cell following the incubation with DHR123 substrates. Data are representative of three independent experiments performed separately. B, Bortezomib; V, Vemurafenib.

Article Snippet: Cell culture The human anaplastic thyroid carcinoma-derived cell lines, SW1736 and KAT18 cells were provided by Dr Xing (University of Johns Hopkins, Baltimore, MD, USA).

Techniques: Staining, Flow Cytometry, Western Blot, Phospho-proteomics, Control, Membrane, Incubation

Journal: Endocrine-related cancer

Article Title: Bortezomib sensitizes thyroid cancer to BRAF inhibitor in vitro and in vivo

doi: 10.1530/ERC-17-0182

Figure Lengend Snippet: Effect of drug combination on xenograft thyroid tumors in mice. Mice were engrafted with 2 × 106 SW1736 cells and treated with Vemurafenib and/or Bortezomib. (A) At the end point after treating with the drug Vemurafenib, Bortezomib or combination (V + B), tumors resected and stained with H&E. (B) Treatment of mice with the drug combination (V + B) produced a synergistic effect (64% tumor size reduction compared to initial tumor size), while Vemurafenib (35%) or Bortezomib (26%) alone slightly increased tumor size compared to initial tumor. Data are expressed as the arithmetic mean ± the standard deviation and considered significant at P < 0.05. (C) Statistical analysis of IHC of Ki-67 in control and treated mice with Vemurafenib, Bortezomib or combination for 4 weeks. Nuclear staining was counted from at least five fields and expressed as percentage, * and ** represent significance at P < 0.05 and P < 0.01, respectively, compared with control (no drug). (D) Statistical analysis of IHC of Cyclin D1 in control and treated mice with Vemurafenib, Bortezomib or combination for 4 weeks.

Article Snippet: Cell culture The human anaplastic thyroid carcinoma-derived cell lines, SW1736 and KAT18 cells were provided by Dr Xing (University of Johns Hopkins, Baltimore, MD, USA).

Techniques: Staining, Produced, Standard Deviation, Control

Journal: Experimental and Therapeutic Medicine

Article Title: HOTAIR is a promising novel biomarker in patients with thyroid cancer

doi: 10.3892/etm.2017.4231

Figure Lengend Snippet: HOTAIR is upregulated in TC cell lines. (A) The expression levels of HOTAIR were detected in WRO, TPC-1 and SW579 cells via RT-qPCR, and HT-ori3 was used as the negative control. (B) The expression levels of HOTAIR were verified in TPC-1 and SW579 cell lines with a HOTAIR knockdown assay. Scr, cells transfected with scramble nucleotide fragments; siRNA, cells transfected with siRNA specifically targeting HOTAIR. The experiments were repeated in triplicate and three independent experiments were performed. *P<0.05; # P<0.01, vs. the control. HOTAIR, HOX transcript antisense RNA; TC, thyroid cancer; siRNA, small interfering RNA; RT-qPCR, reverse transcription-quantitative polymerase chain reaction.

Article Snippet: The HT-ori3 normal human thyroid cell line and human thyroid carcinoma cell lines including WRO, TPC-1 and SW579 were all purchased from Beijing Zhongyuan Ltd. (Beijing, China).

Techniques: Expressing, Quantitative RT-PCR, Negative Control, Transfection, Small Interfering RNA, Real-time Polymerase Chain Reaction

Journal: Journal of Experimental & Clinical Cancer Research : CR

Article Title: LncRNA XIST/miR-34a axis modulates the cell proliferation and tumor growth of thyroid cancer through MET-PI3K-AKT signaling

doi: 10.1186/s13046-018-0950-9

Figure Lengend Snippet: XIST knockdown inhibits the cell and tumor growth of thyroid cancer ( a ) XIST expression in five thyroid cancer cell lines (FTC133, BCPAP, TPC-1, SW1736 and KAT18) and a normal human thyroid epithelium cell line (TEC) was examined using real-time PCR assays. b XIST knockdown was achieved by transfection of si-XIST#1 or si-XIST#2, as confirmed using real-time PCR assays. c - d The cell viability was determined using MTT assays. e - f The DNA synthesis ability was determined using BrdU assays. g - i The tumor volume and tumor weight derived from si-XIST#1 or si-XIST#2-transfected KAT18 cells were examined. j - l The tumor volume and tumor weight derived from si-XIST#1 or si-XIST#2-transfected TPC-1 cells were examined. The data are presented as mean ± SD of three independent experiments. * P < 0.05, ** P < 0.01

Article Snippet: A human follicular thyroid carcinoma cell line, FTC133 derived from a lymph node metastasis of a follicular thyroid carcinoma, a human thyroid cancer papillary cell line, BCPAP, and a normal human thyroid epithelium cell line (TEC) were purchased from the ScienCell Research Laboratories (Carlsbad, CA, USA).

Techniques: Knockdown, Expressing, Real-time Polymerase Chain Reaction, Transfection, DNA Synthesis, Derivative Assay